These transcription factor agonists may be a therapy to dampen the late inflammatory phase of COVID-19 as PPAR-γ agonists such as rosiglitazone can block nuclear factor kappa B (NF-κB)-mediated inflammatory cytokine production in lung epithelial cells [46, 47]. The gene discussed is NFKB1; the disease is COVID-19.